Mostrando 2 resultados de: 2
Origen
scopus(2)
Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: A randomized, parallel, open-label safety study
ArticleAbstract: Background: Delivery of therapeutic agents as erythropoietin (EPO) into Central Nervous System throuPalabras claves:Healthy volunteers, Hematopoietic activity, neurodegenerative diseases, NeuroEPO, Non-hematopoietic recombinant erythropoietin, safety, strokeAutores:Alfonso-Muñoz E., Amaro-González D., Carmen Elena Viada, Díaz-Machado A., Festary-Casanovas T., García-García I., González-Delgado C.A., Jiménez-Rodríguez D., Pérez-Rodríguez S., Piedra-Sierra P., Pomares-Iturralde Y., Santos-Morales O.Fuentes:scopusNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
ReviewAbstract: Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptorPalabras claves:eGFR, glioma, Humanized, Monoclonal antibody, nimotuzumab, Overall survival, SCCHNAutores:Arvind A., Eswaraiah A., Iyer H., Piedra-Sierra P., Ramakrishnan M., Saurez G., Tania CrombetFuentes:scopus